David Arnstein - Profile and Investment Details

Investor Profile

David Arnstein is a Venture Capital, Private Equity Firm based in Milwaukee, Wisconsin, United States with a diverse investment portfolio that includes companies such as Elucent Medical, UpTo, Virent Energy Systems, EnsoData, Invenra, Celleration, Inviragen, IntraLase Corporation, Zystor, Third Wave Technologies, Chromatin, Thalchemy, Madison Vaccines, Alfalight, Nextt, InterSymbol Communications, NeuWave Medical, HealthMyne, Pattern Insight, TomoTherapy, FluGen, BlueWillow Biologics, Roche NimbleGen, Mithridion, SilatronixNeuMoDx Molecular, Corona Optical Systems, ReShape Lifesciences, Prevacept Infection Control, NERITES, Juventas Therapeutics, Promega, Neurovance, SoftSwitching Technologies, Health Scholars, SkySpecs, Delphinus Medical Technologies, Deltanoid Pharmaceuticals, TAI Diagnostics, ProCertus BioPharm, HistoSonics, Aerpio Pharmaceuticals, Eximis Surgical, Tissue Regeneration Systems, LensX Lasers, Incept, Cellectar Biosciences, Gala Biotech, Euthymics Bioscience, Netsocket, Akebia Therapeutics, . Over time, David Arnstein has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether David Arnstein is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Patient Care, Health Care, Hospitals, Wellness, Women Founded, Investment Management, Energy, Healthcare Innovation, Life Science, Portfolio Management, Medical Technologies, Artificial Intelligence (AI), Robotics, Startups, Information Technology (IT), Analytics, Finance, Software, Biotechnology, Medical Devices, Hispanic / Latinx Founded, Productivity Software, Clinical Trials, Digital Health, Renewable Energy, Medical, Information Technology, B2B, Therapeutics, Health Tech, Molecular Diagnostics, Machine Learning, Air Transportation, Pharmaceuticals, Healthcare Technology, Oncology may find it worthwhile to explore potential connections with David Arnstein, as their portfolio suggests a familiarity and interest in this area.

Understanding David Arnstein’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.